Chemoembolization of hepatocellular carcinoma - What to tell the skeptics: Review and meta-analysis

Douglas E. Ramsey, Jean Francois H. Geschwind

Research output: Contribution to journalArticlepeer-review

Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment for patients with unresectable hepatocellular carcinoma (HCC). When untreated, patients with inoperable HCC have a median survival of three months. Given the widespread use of chemoembolization, accurate evidence of the impact of TACE on patient survival is critical. Several review articles have examined randomized controlled trials (RCTs) of TACE; however, these analyses are inherently flawed by including trials in which control groups were treated. There have been only four RCTs comparing TACE to untreated controls to date. None has demonstrated a significant impact of TACE on patient survival. However, in addition to severe methodological flaws, these RCTs were limited by low patient enrollment, precluding any meaningful conclusions. In contrast, several non-randomized trials have clearly demonstrated a significant benefit of TACE on patient survival. New RCTs examining the impact of chemoembolization on survival are urgently needed to provide definitive evidence for the increasing number of patients treated with TACE. A new, well-designed RCT would provide significant insight on the impact of chemoembolization on patient survival.

Original languageEnglish (US)
Pages (from-to)122-126
Number of pages5
JournalTechniques in Vascular and Interventional Radiology
Volume5
Issue number3
DOIs
StatePublished - Sep 2002

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Chemoembolization of hepatocellular carcinoma - What to tell the skeptics: Review and meta-analysis'. Together they form a unique fingerprint.

Cite this